Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 4/20 | 0.53 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.47 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.47 |
| ▸ | SCN2A | Q99250 | 3/20 | 0.47 |
| ▸ | PIM1 | P11309 | 2/20 | 0.46 |
| ▸ | HPGDS | O60760 | 4/20 | 0.45 |
| ▸ | AXL | P30530 | 2/20 | 0.44 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.43 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.43 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | METAP2 | P50579 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL19065542 | 0.91 | NPY5R (0.44) | NPY5RACVR1BTGFBR1SCN2APIM1 | |
| Trifluoroacetic Acid SCHEMBL29675357 | 0.91 | NPY5R (0.44) | NPY5RACVR1BTGFBR1SCN2APIM1 | |
| SCHEMBL19087046 | 0.85 | NPY5R (0.53) | NPY5RSCN2AHPGDS | |
| SCHEMBL19066083 | 0.85 | NPY5R (0.48) | NPY5RTGFBR1SCN2APIM1HPGDS | |
| SCHEMBL19065340 | 0.85 | NPY5R (0.50) | NPY5RSCN2APIM1HPGDS | |
| SCHEMBL19065252 | 0.83 | NPY5R (0.48) | NPY5RTGFBR1SCN2AHPGDSKDM1A | |
| SCHEMBL19065711 | 0.81 | L3MBTL1 (0.54) | NPY5RSCN2AHPGDSALK | |
| SCHEMBL19065477 | 0.81 | NPY5R (0.46) | NPY5RSCN2AHPGDSKDM1A | |
| SCHEMBL19065531 | 0.81 | NPY5R (0.53) | NPY5RSCN2AHPGDSKDM1A | |
| SCHEMBL19065362 | 0.80 | ALK (0.52) | NPY5RPIM1ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11952367-B2 | Pyridine and pyridimine compounds as PI3K-gamma inhibitors | INCYTE CORPORATION (US) | 2024-04-09 | — | — | US | claimed |
| US-20220227736-A1 | PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | INCYTE CORPORATION | 2022-07-21 | — | — | US | claimed |
| US-11352340-B2 | Pyridine and pyridimine compounds as PI3K-gamma inhibitors | INCYTE CORPORATION (US) | 2022-06-07 | — | — | US | claimed |
| EP-3792256-A1 | PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | Incyte Corporation (US) | 2021-03-17 | — | — | EP | claimed |
| EP-3400221-B1 | PYRAZOL / IMIDAZOL SUBSTITUTED PYRIDINES AS PI3K-GAMMA INHIBITORS | INCYTE CORP (US) | 2020-08-26 | — | — | EP | claimed |
| EP-3400221-A1 | PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | Incyte Corporation (US) | 2018-11-14 | — | — | EP | claimed |
| WO-2017120194-A1 | PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | INCYTE CORPORATION (US) | 2017-07-13 | — | — | WO | claimed |
| US-20170190689-A1 | PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | INCYTE CORPORATION | 2017-07-06 | — | — | US | claimed |
| EP-3792256-A1 | PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | Incyte Corporation (US) | 2021-03-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220227736-A1 | PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | PIK3CG, PIK3CD, PIK3CB | NPY5R 4040/4885ACVR1B 3003/4885TGFBR1 1213/4885 |
| US-11352340-B2 | Pyridine and pyridimine compounds as PI3K-gamma inhibitors | PIK3CG, PIK3CD, PIK3CB | NPY5R 4040/4885ACVR1B 3003/4885TGFBR1 1213/4885 |
| US-20170190689-A1 | PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | PIK3CG, PIK3CD, PIK3CB | NPY5R 4040/4885ACVR1B 3003/4885TGFBR1 1213/4885 |
| US-11952367-B2 | Pyridine and pyridimine compounds as PI3K-gamma inhibitors | PIK3CG, PIK3CD, PIK3CB | NPY5R 4040/4885ACVR1B 3003/4885TGFBR1 1213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.